Skip to main content
Clinical Trials/NCT00997815
NCT00997815
Completed
Phase 2

The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis

Siriraj Hospital1 site in 1 country20 target enrollmentDecember 2009

Overview

Phase
Phase 2
Intervention
Botulinum toxin A
Conditions
Recalcitrant Alopecia Totalis
Sponsor
Siriraj Hospital
Enrollment
20
Locations
1
Primary Endpoint
To evaluate the percentage of terminal hair regrowth in recalcitrant alopecia totalis and alopecia universalis after intralesional botulinum toxin A injection
Status
Completed
Last Updated
13 years ago

Overview

Brief Summary

The main purpose of this study is to determine the efficacy of intralesional botulinum toxin type A injection for recalcitrant alopecia totalis and alopecia universalis.

Treatments of recalcitrant alopecia totalis and universalis remains an challenge issue for medical practice.The application of diphenylcyclopropenone (DPCP) is still being an standard treatment for the condition, however, there are at least thirty percentage of patients recalcitrant to this treatment.

The complete etiology of this disease has yet to be clear.Nevertheless,recent studies have demonstrated the hypothesis of neurotransmitter involvements.

There is numerous evidence in support of an imbalance of transmitters, including substance P and Calcitonin gene-related peptide.

Botulinum toxin A injection has been used to treat a neuralgiform headache and diffused alopecia areata. Both headache and hair loss have been made much in improvement. This data may support the neurotransmitter imbalance theory.

The investigators have been informed about possible effects to the alopecia condition, therefore, this study is conducted to assess the efficacy of botulinum toxin A as the novel treatment for recalcitrant alopecia totalis and alopecia universalis.

Registry
clinicaltrials.gov
Start Date
December 2009
End Date
June 2011
Last Updated
13 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Rattapon Thuangtong

Assistant professor

Siriraj Hospital

Eligibility Criteria

Inclusion Criteria

  • All patients must be over 18 years old
  • All patients are diagnosed with alopecia totalis or alopecia universalis
  • The alopecia condition was not responded to any treatments

Exclusion Criteria

  • Having an active inflammation on scalp area
  • Allergic to botulinum toxin A of human albumin
  • Has been diagnosed with neuromuscular disorders
  • Taking any medication that may interfere with botulinum toxin A action
  • Receiving any treatment for alopecia condition within 4 weeks
  • Pregnant , breastfeeding, plan to pregnant patients

Arms & Interventions

Botulinum toxin A

The area of alopecia is splited into experimental and control sides by blocked randomization. Experimental sides injected with botulinum toxin A at 2 units per 0.1 ml of dilution with normal saline entire all area.

Intervention: Botulinum toxin A

Placebo

Using normal saline

Intervention: Normal saline injection

Outcomes

Primary Outcomes

To evaluate the percentage of terminal hair regrowth in recalcitrant alopecia totalis and alopecia universalis after intralesional botulinum toxin A injection

Time Frame: 4 months

Secondary Outcomes

  • To evaluate any possible side effects of intralesional botulinum toxin A injection for alopecia totalis and alopecia universalis(4 months)

Study Sites (1)

Loading locations...

Similar Trials